Concert Pharmaceuticals Inc(CNCE) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.

Current Price

$4.01

RSI

28.453

Beta:

0.554329

February 25, 2021
16M
-16.3M

-46.154 %
416.133 %
-9.289 %
-6.227 %

$7,902,000
$1,077,000
$10,505,000
$143,891,000
$174,000
$66,729,000
633.705 %
-875.395 %
-1269.738 %
82595.977 %
-38250.000 %

$-74,851,000
$-78,166,000
$-55,711,000
$95,339,000
$-50,720,000
$24,603,000
4.429 %
-28.727 %
-271.131 %
153.200 %
-148.507 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.